Ortho Clinical Diagnostics Stocks List
|CEMI||F||Chembio Diagnostics, Inc.||-3.48|
|BIO||B||Bio-Rad Laboratories, Inc.||0.21|
|BIO.B||D||Bio-Rad Laboratories, Inc. Class B||0.00|
|TMO||B||Thermo Fisher Scientific Inc||-0.30|
|OCDX||C||Ortho Clinical Diagnostics plc||1.70|
|IHI||A||iShares U.S. Medical Devices ETF||13.22|
|MJJ||D||MicroSectors Cannabis ETNs||9.9|
|MJO||D||MicroSectors Cannabis 2X Leveraged ETNs||9.9|
|GERM||D||ETFMG Treatments Testing and Advancements ETF||5.71|
|BUL||A||Pacer US Cash Cows Growth ETF||4.9|
View all Ortho Clinical Diagnostics related ETFs...
|2021-04-16||BIO||Upper Bollinger Band Walk||Strength|
|2021-04-16||BIO||Pocket Pivot||Bullish Swing Setup|
|2021-04-16||CEMI||Narrow Range Bar||Range Contraction|
|2021-04-16||CODX||Narrow Range Bar||Range Contraction|
|2021-04-16||CODX||Lizard Bullish||Bullish Day Trade Setup|
|2021-04-16||OCDX||50 DMA Support||Bullish|
|2021-04-16||TMO||Upper Bollinger Band Walk||Strength|
Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing. Ortho serves two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood.
Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. Ortho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York.
In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operates as an independent company.Ortho Clinical Diagnostics (Ortho) unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson. In his first act as Ortho's Chairman and CEO, Dr. Martin D. Madaus announced key appointments in finance, operations, legal and commercial to advance strategic sectors of the In Vitro Diagnostics (IVD) business.